- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Beta Amylase.
Displaying page 1 of 1.
EudraCT Number: 2015-000408-24 | Sponsor Protocol Number: D5551C00002 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005177-21 | Sponsor Protocol Number: 2015-29 | Start Date*: 2016-01-28 |
Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE | ||
Full Title: Dose-Finding of Propranolol in combination with metronomic fixed oral cyclophosphamide based on Bivariate efficacy-tolerability outcome in patients with locally advanced or metastatic angiosarcoma ... | ||
Medical condition: Patients presenting angiosarcomas disease | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004591-35 | Sponsor Protocol Number: ADVL1211 | Start Date*: 2018-12-14 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP) | ||
Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS | ||
Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-001803-35 | Sponsor Protocol Number: DCC-2618-03-002 | Start Date*: 2019-04-01 | |||||||||||
Sponsor Name:Deciphera Pharmaceuticals, LLC | |||||||||||||
Full Title: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib | |||||||||||||
Medical condition: Patients with Advanced Gastrointestinal Stromal Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) NO (Ongoing) ES (Ongoing) SE (Completed) BE (Completed) NL (Ongoing) HU (Completed) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002446-76 | Sponsor Protocol Number: DCC-2618-03-001 | Start Date*: 2018-03-29 |
Sponsor Name:Deciphera Pharmaceuticals, LLC | ||
Full Title: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment... | ||
Medical condition: Patients with AdvanCed Gastrointestinal Stromal TUmorS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Prematurely Ended) BE (Completed) ES (Prematurely Ended) PL (Prematurely Ended) FI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001381-96 | Sponsor Protocol Number: LG_T1_EGP | Start Date*: 2014-06-17 |
Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel | ||
Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept... | ||
Medical condition: Diabetes Mellitus Type 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004285-53 | Sponsor Protocol Number: VA 2008/28 | Start Date*: 2008-12-19 | |||||||||||
Sponsor Name:Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque | |||||||||||||
Full Title: Etude de phase I-II évaluant l’association Sorafénib (NEXAVAR®) et Irinotecan en deuxième ligne ou plus de traitement des cancers colorectaux métastatiques avec une mutation de Kras – NEXIRI | |||||||||||||
Medical condition: Cancer du côlon ou du rectum métastatique prouvé histologiquement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003739-32 | Sponsor Protocol Number: 1801 | Start Date*: 2020-02-28 | ||||||||||||||||
Sponsor Name:Actuate Therapeutics Inc | ||||||||||||||||||
Full Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignan... | ||||||||||||||||||
Medical condition: Refractory Hematologic Malignancies or Solid Tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000687-30 | Sponsor Protocol Number: AROAPOC3-2001 | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe Hypertriglyceridemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020121-41 | Sponsor Protocol Number: 11728 | Start Date*: 2011-01-17 | |||||||||||
Sponsor Name:Bayer Health Care AG, D-51368 Leverkusen | |||||||||||||
Full Title: An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fl... | |||||||||||||
Medical condition: Metastatic adenocarcinoma of the colon or rectum (metastatic CRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.